{
    "root": "36382697-0804-0a8f-e063-6394a90ae02c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ciprofloxacin",
    "value": "20250528",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "CIPROFLOXACIN HYDROCHLORIDE",
            "code": "4BA73M5E37"
        }
    ],
    "indications": "ciprofloxacin fluoroquinolone antibacterial indicated adults ( 18 years age older ) following infections caused designated , susceptible bacteria pediatric patients indicated : skin skin structure infections ( 1.1 ) bone joint infections ( 1.2 ) complicated intra-abdominal infections ( 1.3 ) infectious diarrhea ( 1.4 ) typhoid fever ( enteric fever ) ( 1.5 ) uncomplicated cervical urethral gonorrhea ( 1.6 ) inhalational anthrax post-exposure adult pediatric patients ( 1.7 ) plague adult pediatric patients ( 1.8 ) chronic bacterial prostatitis ( 1.9 ) lower respiratory tract infections ( 1.10 ) acute exacerbation chronic bronchitis urinary tract infections ( 1.11 ) urinary tract infections ( uti ) acute uncomplicated cystitis complicated uti pyelonephritis pediatric patients acute sinusitis ( 1.12 ) usage reduce development drug-resistant bacteria maintain effectiveness ciprofloxacin antibacterial drugs , ciprofloxacin used treat prevent infections proven strongly suspected caused bacteria . ( 1.13 )",
    "contraindications": "ciprofloxacin tablets administered orally described appropriate guidelines tables .",
    "warningsAndPrecautions": "ciprofloxacin tablets usp 500 mg available white colored , biconvex , capsule shaped , film coated tablets , debossed ' p ' one side '500 ' side containing ciprofloxacin hydrochloride , usp equivalent 500 mg ciprofloxacin . ndc : 70518-0368-00 ndc : 70518-0368-01 ndc : 70518-0368-02 ndc : 70518-0368-03 ndc : 70518-0368-04 ndc : 70518-0368-05 packaging : 30 1 blister pack packaging : 20 1 bottle plastic packaging : 20 1 blister pack packaging : 14 1 blister pack packaging : 14 1 bottle plastic packaging : 10 1 bottle plastic store 20° 25°c ( 68° 77° f ) ; excursions permitted 15° 30°c ( 59° 86° f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "known hypersensitivity ciprofloxacin quinolones ( 4.1 , 5.6 , 5.7 ) concomitant tizanidine ( 4.2 )",
    "indications_original": "Ciprofloxacin is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated: Skin and Skin Structure Infections ( 1.1 ) Bone and Joint Infections ( 1.2 ) Complicated Intra-Abdominal Infections ( 1.3 ) Infectious Diarrhea ( 1.4 ) Typhoid Fever (Enteric Fever) ( 1.5 ) Uncomplicated Cervical and Urethral Gonorrhea ( 1.6 ) Inhalational Anthrax post-exposure in adult and pediatric patients ( 1.7 ) Plague in adult and pediatric patients ( 1.8 ) Chronic Bacterial Prostatitis ( 1.9 ) Lower Respiratory Tract Infections ( 1.10 ) o Acute Exacerbation of Chronic Bronchitis Urinary Tract Infections ( 1.11 ) o Urinary Tract Infections (UTI) o Acute Uncomplicated Cystitis o Complicated UTI and Pyelonephritis in Pediatric Patients Acute Sinusitis ( 1.12 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin and other antibacterial drugs, ciprofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.13 )",
    "contraindications_original": "Ciprofloxacin tablets should be administered orally as described in the appropriate Dosage Guidelines tables.",
    "warningsAndPrecautions_original": "Ciprofloxacin tablets USP 500 mg are available as white colored, biconvex, capsule shaped, film coated tablets, debossed 'P' on one side and '500' on the other side containing ciprofloxacin hydrochloride, USP equivalent to 500 mg of ciprofloxacin.\n                  \n                  NDC: 70518-0368-00\n                  NDC: 70518-0368-01\n                  NDC: 70518-0368-02\n                  NDC: 70518-0368-03\n                  NDC: 70518-0368-04\n                  NDC: 70518-0368-05\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 20 in 1 BOTTLE PLASTIC\n                  PACKAGING: 20 in 1 BLISTER PACK\n                  PACKAGING: 14 in 1 BLISTER PACK\n                  PACKAGING: 14 in 1 BOTTLE PLASTIC\n                  PACKAGING: 10 in 1 BOTTLE PLASTIC\n                  \n                  Store at 20° to 25°C (68° to 77° F); excursions permitted to 15° to 30°C (59° to 86° F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Known hypersensitivity to ciprofloxacin or other quinolones ( 4.1 , 5.6 , 5.7 ) Concomitant administration with tizanidine ( 4.2 )"
}